Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivermectin 0.5% cream for demodicidosis
NCT02036229Phase 3Unknown
- Sponsor
- Rabin Medical Center
- Start
- Feb 2014
- Primary completion
- Dec 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ivermectin in demodicosis and papulopustular rosacea, sponsored by Rabin Medical Center. Primary endpoint: Mite density in skin surface biopsy at 5 months. Status: unknown.
02
Drugs
ivermectin
03
Conditions
demodicosispapulopustular rosacea
Beyond the preview
Go deeper on NCT02036229.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02036229.